-
1دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
2دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
3دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
4دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
5دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
6دورية أكاديمية
لا يتم عرض هذه النتيجة على الضيوف.
تسجيل الدخول للوصول الكامل. -
7دورية أكاديمية
المؤلفون: Li W; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Crouse KK; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Alley J; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Frisbie RK; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Fish SC; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Andreyeva TA; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Reed LA; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Thorn M; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., DiMaggio G; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Donovan CB; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Bennett D; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Garren J; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Oziolor E; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Qian J; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Newman L; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Vargas AP; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Kumpf SW; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Steyn SJ; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Schnute ME; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Thorarensen A; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Hegen M; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Stevens E; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Collinge M; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Lanz TA; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Vincent F; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Vincent MS; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut., Berstein G; Inflammation and Immunology Research Unit (W.L., K.K.C., J.A., S.C.F., T.A.A., M.H., M.S.V., G.B.), Biostatistics (D.B., J.G.), and Medicine Design (S.J.S., M.E.S., A.T.), Pfizer, Inc., Cambridge, Massachusetts, and Primary Pharmacology Group (R.K.F., F.V.), Clinical Biomarkers (M.T., E.S.), and Drug Safety Research and Development (L.A.R., G.D., C.B.D., E.O., J.Q., L.N., A.P.V., S.W.K., M.C., T.A.L.), Pfizer, Inc., Groton, Connecticut Gabriel.Berstein@pfizer.com.
المصدر: The Journal of pharmacology and experimental therapeutics [J Pharmacol Exp Ther] 2023 Jul; Vol. 386 (1), pp. 80-92. Date of Electronic Publication: 2023 May 04.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Society for Pharmacology and Experimental Therapeutics Country of Publication: United States NLM ID: 0376362 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1521-0103 (Electronic) Linking ISSN: 00223565 NLM ISO Abbreviation: J Pharmacol Exp Ther Subsets: MEDLINE
مواضيع طبية MeSH: Chemokines, CC*/genetics , Interleukin-23*, Humans ; Animals ; Mice ; Receptors, CCR7 ; Ligands ; T-Lymphocytes ; Inflammation ; Receptors, CCR6
-
8دورية أكاديمية
المؤلفون: Schnute ME; Medicine Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States., Trujillo JI; Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States., Lee KL; Medicine Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States., Unwalla R; Medicine Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States., Vajdos FF; Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States., Kauppi B; Karo Pharma AB, 111 48 Stockholm, Sweden., Nuhant P; Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States., Flick AC; Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States., Crouse KK; Inflammation and Immunology Research, Pfizer Inc., Cambridge, Massachusetts 02139, United States., Zhao Y; Inflammation and Immunology Research, Pfizer Inc., Cambridge, Massachusetts 02139, United States., Samuel A; Drug Product Design, Pfizer Inc., San Diego, California 92121, United States., Lombardo V; Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States., Taylor AP; Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States., Brault AL; Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States., Knafels JD; Medicine Design, Pfizer Inc., Groton, Connecticut 06340, United States., Vazquez ML; Medicine Design, Pfizer Inc., Cambridge, Massachusetts 02139, United States., Berstein G; Inflammation and Immunology Research, Pfizer Inc., Cambridge, Massachusetts 02139, United States.
المصدر: ACS medicinal chemistry letters [ACS Med Chem Lett] 2023 Jan 18; Vol. 14 (2), pp. 191-198. Date of Electronic Publication: 2023 Jan 18 (Print Publication: 2023).
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101521073 Publication Model: eCollection Cited Medium: Print ISSN: 1948-5875 (Print) Linking ISSN: 19485875 NLM ISO Abbreviation: ACS Med Chem Lett Subsets: PubMed not MEDLINE
-
9دورية أكاديمية
المؤلفون: Schnute ME, Wennerstål M; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Alley J, Bengtsson M; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Blinn JR, Bolten CW, Braden T, Bonn T; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Carlsson B; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Caspers N; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Chen M; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Choi C; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Collis LP, Crouse K, Färnegårdh M; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Fennell KF; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Fish S, Flick AC; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Goos-Nilsson A; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Gullberg H; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Harris PK, Heasley SE; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Hegen M, Hromockyj AE, Hu X, Husman B; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Janosik T; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Jones P, Kaila N, Kallin E; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Kauppi B; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Kiefer JR, Knafels J; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Koehler K; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Kruger L; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Kurumbail RG; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Kyne RE Jr; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Li W, Löfstedt J; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Long SA, Menard CA; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Mente S, Messing D, Meyers MJ, Napierata L, Nöteberg D; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Nuhant P; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Pelc MJ, Prinsen MJ, Rhönnstad P; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Backström-Rydin E; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Sandberg J; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Sandström M; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Shah F, Sjöberg M; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Sundell A; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Taylor AP; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Thorarensen A, Trujillo JI; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Trzupek JD, Unwalla R, Vajdos FF; Medicine Design , Pfizer Inc. , Groton , Connecticut 06340 , United States., Weinberg RA, Wood DC, Xing L, Zamaratski E; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Zapf CW, Zhao Y, Wilhelmsson A; Karo Bio AB (now Karo Pharma AB) , 111 48 Stockholm , Sweden., Berstein G
المصدر: Journal of medicinal chemistry [J Med Chem] 2018 Dec 13; Vol. 61 (23), pp. 10415-10439. Date of Electronic Publication: 2018 Sep 09.
نوع المنشور: Journal Article; Research Support, Non-U.S. Gov't
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 9716531 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1520-4804 (Electronic) Linking ISSN: 00222623 NLM ISO Abbreviation: J Med Chem Subsets: MEDLINE
مواضيع طبية MeSH: Drug Design* , Drug Inverse Agonism*, Nuclear Receptor Subfamily 1, Group F, Member 3/*agonists , Pyridines/*administration & dosage , Pyridines/*pharmacology, Administration, Oral ; Animals ; Biological Availability ; Drug Evaluation, Preclinical ; Humans ; Mice ; Pyridines/pharmacokinetics ; Th17 Cells/drug effects ; Th17 Cells/metabolism
-
10دورية أكاديمية
المؤلفون: Schnute ME; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Benoit SE; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Buchler IP; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Caspers N; Medicine Design, Pfizer, Groton, Connecticut 06340, United States., Grapperhaus ML; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States., Han S; Medicine Design, Pfizer, Groton, Connecticut 06340, United States., Hotchandani R; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Huang N; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Hughes RO; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Juba BM; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Kim KH; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Liu E; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., McCarthy E; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Messing D; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Miyashiro JS; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Mohan S; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., O'Connell TN; Medicine Design, Pfizer, Groton, Connecticut 06340, United States., Ohren JF; Medicine Design, Pfizer, Groton, Connecticut 06340, United States., Parikh MD; Medicine Design, Pfizer, Groton, Connecticut 06340, United States., Schmidt M; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States., Selness SR; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States., Springer JR; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Thanabal V; Medicine Design, Pfizer, Groton, Connecticut 06340, United States., Trujillo JI; Medicine Design, Pfizer, Groton, Connecticut 06340, United States., Walker DP; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States., Wan ZK; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Withka JM; Medicine Design, Pfizer, Groton, Connecticut 06340, United States., Wittwer AJ; Medicinal Chemistry and Inflammation and Immunology Research, Pfizer, St. Louis, Missouri 63017, United States., Wood NL; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Xing L; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Zapf CW; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States., Douhan J 3rd; Medicine Design and Inflammation and Immunology Research, Pfizer, Cambridge, Massachusetts 02139, United States.
المصدر: ACS medicinal chemistry letters [ACS Med Chem Lett] 2018 Dec 03; Vol. 10 (1), pp. 80-85. Date of Electronic Publication: 2018 Dec 03 (Print Publication: 2019).
نوع المنشور: Journal Article
بيانات الدورية: Publisher: American Chemical Society Country of Publication: United States NLM ID: 101521073 Publication Model: eCollection Cited Medium: Print ISSN: 1948-5875 (Print) Linking ISSN: 19485875 NLM ISO Abbreviation: ACS Med Chem Lett Subsets: PubMed not MEDLINE